Molecular targets and regulators of cardiac hypertrophy

Pharmacological Research

Volumn 61, Issue 4, 2010, Pages 269-280

  Rohini, Agrawal ^a   Agrawal, Neeraj ^a   Koyani, Chintan N ^a   Singh, Randhir ^b  

^a JSS COLLEGE OF PHARMACY   (India)

^b PUNJABI UNIVERSITY   (India)

Author keywords

Cardiomyocyte; Hypertrophy

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HISTONE DEACETYLASE; INTERLEUKIN 6; JANUS KINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; NATRIURETIC FACTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SODIUM PROTON EXCHANGE PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CYTOKINE RELEASE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC POLYMORPHISM; HEART FAILURE; HEART PERFUSION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TRANSCRIPTION REGULATION;

CARDIOMEGALY; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; GENETIC VARIATION; HEART FAILURE; HUMANS; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 77649342305     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.11.012     Document Type: Review

References (162)

1. Frey N., Katus H.A., Olson E.N., and Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
2. Levy D., Garrison R.J., and Savage D.D. Prognosis implications of echocardiographically determined left ventricluar mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
3. Ho Y.L., Wu C.C., Lin L.C., Huang C.H., and Chen W.J. Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography effect of the left ventricular hypertrophy. Cardiology 95 (1998) 1592-1600
4. Dorn G.W., Robbins J., and Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ Res 92 (2003) 1171-1175
5. Aaronson K.D., and Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. J Am Med Assoc 296 (2006) 1465-1466
6. Nadal-Ginard B., Kajstura J., Leri A., and Anversa P. Myocyte death, growth and regeneration in cardiac hypertrophy and failure. Circ Res 92 (2003) 139-150
7. Beltrani A.P., Urbanek K., Kajstura J., Yan S.M., and Finato N. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344 (2001) 1750-1757
8. Passier R., Zeng H., Frey N., Naya F.J., and Nicol R.L. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 105 (2000) 1395-1406
9. Kajstura J., Zhang X., Liu Y., Szoke E., and Cheng W. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 92 (1995) 2306-2317
10. Mehra M.R., Uber P.A., and Francis G.S. Heart failure therapy at a crossroad: are there limits to the neurohormonal model. J Am Coll Cardiol 41 (2003) 1606-1610
11. Sadoshima J., Takahashi T., Jahn L., and Izumo S. Roles of mechanosensitive ion channels, cytoskeleton and contractile activity in stretch-induced immediate early gene expression and hypertrophy of cardiac myocytes. Prov Natl Acad Sci USA 89 (1992) 9905-9909
12. Chien K.R. Genomic circuits and the integrative biology of cardiac diseases. Nature 407 (2000) 227-232
13. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
14. Hornig B., Arakawa M., Kohler C., and Drexeler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97 (1998) 363-368
15. Sepúlveda J.L., Vlahopoulos S., Iver D., Belaguli N., and Schwartz R.J. Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity. J Biol Chem 277 (2002) 25775-26782
16. 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275 (2000) 13721-13726
17. Littion A.L., Michael J.B., Arnould E., Carro P., and Soubrier F. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. Am J Physiol 251 (1986) 890-896
18. De Windt L.J., Lim H.W., Bueno O.F., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98 (2001) 3322-3327
19. Sussman M.A., Welch S., Walker A., et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac 1. J Clin Invest 102 (1998) 929-937
20. ++-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res 63 (2004) 450-457
21. Mendelsohn M.E. Viagra: now mending hearts. Nat Med 11 (2005) 115-116
22. Wollert K.C., Fiedler B., Gambaryan S., et al. Gene transfer of cGMP dependent protein kinase 1 enhances the antihypertrophic effects nitric oxide in cardiomyocytes. Hypertrnsion 39 (2002) 87-92
23. Fiedler B., Lohmann S.M., Smolenski A., et al. Inhibition of calcineurin-NFAT signaling by cGMP dependent protein kinase type 1 in cardiac myocytes. Proc Natl Sci USA 99 (2002) 11363-11368
24. 2-adrenergic receptors delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphotidylinositol 3-kinase. Circ Res 87 (2000) 1172-1179
25. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98 (2001) 1607-1612
26. Oudit G.Y., Crackower M.A., Eriksson U., et al. Phosphoinositide 3-kinase γ-deficient mice are protected from isoprotenerol-induced heart failure. Circulation 108 (2003) 2147-2152
27. Meguro T., Hong C., Asai K., et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84 (1999) 735-740
28. McKinsey T.A., Zhang C.L., and Olsen E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27 (2002) 40-47
29. Youn H.D., Chatila T.A., and Liu J.O. Integration of calcineurin and MEF2 signals by the coactivator p300 during T cell apoptosis. EMBO J 19 (2000) 4323-4331
30. Bohm M., Gierschik P., Knorr A., Schmidt U., Weismann K., and Erdmann E. Cardiac adenylyl cyclase, beta-adrenergic receptors, and G-proteins in salt-sensitive hypertension. Hypertension 22 (1993) 715-727
31. Davidson S.M., Townsend P.A., Carroll C., et al. The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin. ChemBioChem 6 (2005) 162-170
32. Molkentin J.D., and Olson E.N. GATA4: a novel transcriptional regulator of cardiac hypertrophy?. Circulation 96 (1997) 3833-3835
33. Ding B., Price R.L., Borg T.K., Weinberg E.O., Halloran P.F., and Lorell B.H. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84 (1999) 729-734
34. Marian A.J. Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans. J Mol Cell Cardiol 41 (2006) 11-13
35. Molkentin J.D., and Dorn G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
36. Arimoto T., Takeishi Y., Takahashi H., et al. Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation 113 (2006) 60-66
37. Proud C.G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63 (2004) 403-423
38. Van Vliet P.D., Burchell H.B., and Titus J.L. Focal myocarditis associated with pheochromocytoma. N Engl J Med 274 (1966) 1102-1108
39. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocytes survival in response to pressure overload. Circulation 110 (2004) 718-723
40. Ichida M., and Finkel T. Ras regulated NFAT3 activity in cardiac myocytes. J Biol Chem 276 (2001) 3524-3530
41. Hoshijima M., Sah V.P., Wang Y., Chien K.R., and Brown J.H. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes: involvement of Rho Kinase. J Biol Chem 273 (1998) 7725-7730
42. Charron F., Tsimiklis G., Arcand M., et al. Tissue-specific GATA factors are transcriptional effectors of small GTPase RhoA. Genes 15 (2001) 2702-2719
43. Adams J.W., Sakata Y., Davis M.G., et al. Enhanced Gαq signaling: a common signaling pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95 (1998) 1140-1142
44. Akhtar S.A., Luttrell L.M., Rockmann H.A., Iaccarino G., Lefkowitz R.J., and Koch W.J. Targeting the receptor Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280 (1998) 574-577
45. Vatner D.E., Yang G.P., Geng Y.J., Asai K., and Yun J.S. Determinants of the cardiomyopathic phenotype in chimeric mice overexpressing cardiac Gsalpha. Circ Res 86 (2000) 802-806
46. 1-adrenergic stimulation. J Biol Chem 269 (1994) 13490-13496
47. Wang Y. Signal transduction in cardiac hypertrophy-dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol 1 (2001) 134-140
48. Clerk A., and Sugden P.H. Untangling the web: specific signaling from PKC isoforms to MAP cascades. Circ Res 89 (2001) 847-849
49. Garrington T.P., and Johnson G.L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11 (1998) 211-218
50. Paul A., Wilson S., Belham C.M., et al. Stress-activated protein kinases: activation, regulation and function. Cell Signal 9 (1997) 403-410
51. Davis F.J., Pillai J.B., Gupta M., and Gupta M.P. Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of α-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. Am J Physiol Heart Circ Physiol 288 (2005) H1477-H1490
52. Komuro I., and Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 27 (1993) 1144-1149
53. Soeki T., Kishimoto I., Okumura H., et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45 (2005) 608-616
54. 2-terminal kinase activation in the heart: evidence of crosstalk between cardiac hypertrophic signaling pathways. J Biol Chem 275 (2000) 13571-13579
55. Takeishi Y., Ping P., Bolli R., Kirkpatrick D.L., Hoit B.D., and Walsh R.A. Transgenic overexpression of constitutively active protein kinase C-ε causes concentric cardiac hypertrophy. Circ Res 86 (2000) 1218-1223
56. Wang D., Chang P.S., Wang Z., Sutherland L., and Richardson J.A. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105 (2001) 851-862
57. Nemoto S., Sheng Z., and Lin A. Opposing effects of Jun kinase and p38 mitogen activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 18 (1998) 3518-3526
58. Mochly-Rosen D., Wu G., Hahn H., et al. Cardiotrophic effects of protein kinase C: analysis by in vivo modulation of PKC translocation. Circ Res 86 (2000) 1173-1179
59. Craig R., Wagner M., McCardle T., Craig A.G., and Glembotski C.C. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. J Biol Chem 276 (2001) 37621-37629
60. Zolk O., Ng L.L., O'Brien R.J., Weyand M., and Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 106 (2002) 1442-1446
61. Gonzalez A., Ravassa S., Loperena I., et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 25 (2007) 2148-2157
62. Fukuzawa J., Booz G.W., Hunt R.A., et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 35 (2000) 1191-1196
63. SanoM, Fukuda K., KodamaH, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 275 (2000) 29717-29723
64. Kodama H., Fukuda K., Pan J., et al. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81 (1997) 656-663
65. Kunisada K., Hirota H., Fujio Y., et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiacmyocytes. Circulation 94 (1996) 2626-2632
66. Luedde M., Hugo A., and Frey N. Novel molecular targets in treatment of cardiac hypertrophy. Recent Patents on Cardiovascular drug discovery. Circulation 1 (2006) 1-20
67. Takano H., Komuro I., Zou Y., Kudoh S., Yamazaki T., and Yazaki Y. Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Lett 379 (1996) 255-259
68. Morgan H.E., Xenophontos X.P., and Hanada T. Strech anabolism transduction. J Appl Cardiol 4 (1989) 415-422
69. Baker K.M., Singeer H.A., and Aceto J.F. Angiotensin II receptor stimulation of cytosolic free calcium and inositol phosphates in chick myocytes. J Pharmacol Exp Ther 51 (1989) 558-578
70. Sadoshima J., and Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 77 (1995) 1040-1052
71. Parker T.G., Packer S.E., and Schneider M.D. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 85 (1990) 507-514
72. Cummins P. Fibroblast and transforming growth factor expression in the cardiac myocyte. Cardiovasc Res 27 (1993) 1150-1154
73. Long C.S., Henrich C.J., and Simpson P.C. A growth factor for cardiac myocytes is produced by cardiac neo-myocytes. Cell Reg 2 (1991) 1081-1085
74. Ren J., Samson W.K., and Sowers J.R. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 31 (1999) 2049-2061
75. Dhand R., Hara K., Hiles I., et al. PI3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 13 (1994) 511-521
76. Delaughter M.C., Taffet G.E., Fiorotto M.L., Entman M.L., and Schwartz R.J. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J 13 (1999) 1923-1929
77. Piek E., Heldin C.H., and Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13 (1999) 2105-2124
78. Massague J. How cells read TGF-β signals. Natl Rev Mol Cell Biol 1 (2000) 169-178
79. Xenopnontos X.P., Watson P.A., Chua B.H.L., Haneda T., and Morgan H.E. Increased cAMP content accelerated protein synthesis in rat heart. Circ Res 65 (1989) 647-656
80. Chua B.H.L., Russo L.A., Gordon E.E., Kleinhans B.J., and Morgan H.E. Faster ribosome synthesis induced by elevated aortic pressure in rat hearts. Am J Physiol 252 (1987) C323-C327
81. Bustamante J.O., Rukundin A., and Sachs F. Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol 17 (1991) S11-23
82. Kent R.L., Hoober K., and Cooper C. Load responsiveness of protein synthesis in adult mammalian myocardium: role of cardiac deformation linked to sodium influx. Circ Res 64 (1989) 74-85
83. Spirito P., Fu Y.-M., Zu Z.-X., Epstein S.E., and Casscells W. Immunohistochemical localization of basic and acidic fibroblast growth factors in the developing rat heart. Circulation 84 (1991) 322-332
84. Schwartz J.C., Gross C., Lococomte J.M., and Bralet J. Minireview Enkaphalinase. Inhibitory protection of endogenous ANF agonist inactivation and potential therapeutic applications. Life Sci 47 (1990) 1279-1297
85. Day M.L., Schwartz D., Wigand S., et al. Ventricular atriopeptin: unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension 9 (1987) 485-491
86. Needleman P., Blaine E.H., Greenwald J.E., et al. The biochemical pharmacology of atrial peptides. Annu Rev Pharmacol Toxicol 29 (1989) 23-54
87. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
88. Hom J.G., Grant S.K., Wolfe G., et al. Lipopolysaccharide-induced hypotension and a vascular hyperreactivity in the rat: tissue analysis of nitric oxide synthase mRNA and protein expression in the presence of dexamethasone, NG-monoethyl-l-arginine or indomethacin. J Pharmacol Exp Ther 272 (1995) 452-459
89. Vidal M.J., Romero J.C., and Vanhoutte P.M. Endothelial-derived relaxing factor inhibits renin release. Eur J Pharmacol 149 (1988) 401-402
90. Garg V.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
91. Barett M.L., Willis A.L., and Vane J.R. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents Actions 27 (1987) 488-491
92. Shiota N., Rysa J., Kovanen P.T., Rusokaho H., Kokkonen J.O., and Lindstedt K.A. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 21 (2003) 1935-1936
93. Barnes P.J., and Karin M. Nuclear factor kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
94. Frantz S., Frracarollo D., Wagner H., et al. Sustained activation of nuclear factor kappa B and activator protein-1 in chronic heart failure. Cardiovasc Res 57 (2003) 749-756
95. Yamamoto K., Ohki R., Lee R.T., et al. Peroxisome proliferator activated receptor-γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
96. Young M.E., Laws F.A., Goodwin G.W., et al. Reactivation of peroxisome proliferator activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276 (2001) 44390-44395
97. Czuberyt M.P., McAnally J., Fishman G.I., et al. Regulation of peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDACs. Proc Natl Acad Sci USA 100 (2003) 1711-1716
98. Mallat Z., Philip I., Lebert M., Chatel D., Maclouf J., and Teegdi A. Elevated levels of 8-iso-prostaglandin F2 alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stressing ventricular dilatation and progression to heart failure. Circulation 97 (1998) 1536-1539
99. Maak C., Kartes T., Kitter H., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac-1 GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
100. Heymes C., Bendall J.K., Rataczak P., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41 (2003) 2164-2171
101. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 (2001) 2407-2411
102. Hornig B., Arakawa M., Kohler C., and Drexeler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97 (1998) 7725-7730
103. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 (2004) 718-723
104. Janssens S., Pokreisz P., Schoonjans L., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase-3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94 (2004) 1256-1262
105. Bril A., and Feurstein G.Z. The role of IL-6 and related cytokines in myocardial remodeling and inflammation-implication for cardiac hypertrophy and heart failure. In: Feurstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basal, Switzerland 111-127
106. Stephanou A. Role of STAT-1 and STAT-3 in ischemia/reperfusion injury. J Cell Mol Med 8 (2004) 519-525
107. Harada M., Qin Y., Takano H., et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the JAK-STAT pathway in cardiomyocytes. Nat Med 11 (2005) 305-311
108. Wang T.L., Yang Y.H., Chang H., and Hung C.R. Angiotensin II signals mechanical-stretch induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 37 (2004) 785-794
109. Mascareno E., and Siddiqui M.A. The role of JAK/STAT signaling in heart tissue rennin angiotensin system. Mol Cell Biochem 212 (2000) 171-175
110. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113 (2003) 673-676
111. Farh K.K., Grimson A., Jan C., et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 310 (2005) 1817-1821
112. Pasquinelli A.E., Hunter S., and Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev 15 (2005) 200-205
113. Cullen B.R. Transcription and processing of human microRNA precursors. Mol Cell 16 (2004) 861-865
114. Lee Y., Jeon K., Lee J.T., Kim S., and Kim V.N. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21 (2002) 4663-4670
115. Lee Y., Ahn C., Han J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425 (2003) 415-419
116. Bartel D.P. Cell 116 (2004) 281-297
117. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
118. Cheng Y., Ji R., Yue J., et al. MicroRNAs are aberrantly expressed in hypertrophic heart. Do they play a role in cardiac hypertrophy?. Am J Pathol 170 (2007) 1831-1840
119. Kiriakidou M. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell 129 (2007) 1141-1151
120. Bagga S. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122 (2005) 553-563
121. Humphreys D.T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA 102 (2005) 16961-16966
122. Elizabeth S., and Antoine B. Implication of microRNAs in the cardiovascular system. Curr Opin Pharmacol 8 (2008) 181-188
123. Valencia-Sanchez M.A. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20 (2006) 515-524
124. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116 (2004) 281-297
125. Bauersachs J., and Thum T. MicroRNAs in the broken heart. Eur J Clin Invest 37 (2007) 829-833
126. Bernstein E., Kim S.Y., Carmell M.A., et al. Dicer is essential for mouse development. Nat Genet 35 (2003) 215-217
127. Krek A. Combinatorial microRNA target predictions. Nat Genet 37 (2005) 495-500
128. Thum T., Galuppo P., Wolf C., Fiedler J., et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116 (2007) 258-267
129. Van Rooij E., Sutherland L.B., Qi X., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103 (2006) 18255-18260
130. Zhao Y., Ransom J.F., Li A., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129 (2007) 303-317
131. Giraldez A.J., Cinalli R.M., Glasner M.E., et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science 308 (2005) 833-838
132. Sayed D., Hong C., Chen I.Y., Lypowy J., and Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100 (2007) 416-424
133. Care A., Catalucci D., Felicetti F., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13 (2007) 613-618
134. Thomas E.C., and Da-Zhi W. Taking microRNAs to heart. Trends Mol Med 14 (2008) 254-260
135. DeBoer R.A., Pinto Y.M., and VanVeldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10 (2003) 113-126
136. Hilfiker-Kleiner D., Limbourg A., and Drexler H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 15 (2005) 152-157
137. Carmeliet P., Ng Y.S., Nuyens D., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5 (1999) 495-502
138. Gavin J.B., Maxwell L., and Edgar S.G. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 30 (1998) 2531-2540
139. Sano M., Minamino T., Toko H., et al. Nature 446 (2007) 444-448
140. Shiojima I., and Walsh K. Genes Dev 20 (2006) 3347-3365
141. Scott JD, Coghlan VM, Howard M, Galantin WM. US5,807,693 (1998).
142. Taigen T., De Windt L.J., Lim H.W., and Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 97 (2000) 1196-1201
143. Fuentes J.J., Pritchard M.A., Planas A.M., Bosch A., Ferrer I., and Estivill X. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 4 (1995) 1935-1944
144. Kingsbury T.J., and Cunningham K.W. A conserved family of calcineurin regulators. Genes Dev 14 (2000) 1595-1604
145. Olson EN, Frey N. US20040,186,275A1 (2004).
146. Knoll R., Hoshijima M., Hoffman H.M., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111 (2002) 943-955
147. Nicol R.L., Frey N., and Olson E.N. From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu Rev Genom Hum Genet 1 (2000) 179-223
148. Richard P., Charron P., Carrier L., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107 (2003) 2227-2232
149. Lowey S. Functional consequences of mutations in themyosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 12 (2002) 348-354
150. Palmiter K.A., Tyska M.J., Haeberle J.R., Alpert N.R., Fananapazir L., and Warshaw D.M. R403Q and L908V mutant beta-cardiacmyosin frompatients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil 21 (2000) 609-620
151. Cuda G., Fananapazir L., Epstein N.D., and Sellers J.R. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 18 (1997) 275-283
152. Rigor D.L., Bodyak N., Bae S., et al. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cβ2 in the regulation of physiologic developmental hypertrophy and heart function. Am J Physiol Heart Circ Physiol 18 (2009) 275-283
153. Lupu F., Terwilliger J.D., Lee K., Segre G.V., and Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 229 (2001) 141-162
154. Oudit G.Y., Kozieradzki I., Sarao R., et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37 (2004) 449-471
155. McMullen J.R., Kang P.M., Douglas P.S., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100 (2003) 12355-12360
156. Antos C.L., McKinsey T.A., Frey N., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 2 (2002) 907-912
157. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 (2004) 233-242
158. Obataa K., Nagatab K., Iwaseb M., et al. Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Biophs Res Commun 338 (2005) 1299-1305
159. Lezoualc'h F., Métrich M., Hmitou I., Duquesnes N., and Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 44 (2008) 623-632
160. Planavila A., Laguna J.C., and Vázquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation. Biochim Biophys Acta 1687 (2005) 76-83
161. Sussman M.A., Lim H.W., Gude N., et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281 (1998) 1690-1693
162. Yamazaki T., Komuro I., Shiojima I., and Yazaki Y. The molecular mechanism of cardiac hypertrophy and failure. Ann New York Acad Sci 874 (1999) 38-48